Scientific Workshops
Scientific Workshops are interactive discussions covering the latest scientific developments in a range of hematologic topics. The 2025 Scientific Workshops will take place on Friday, December 5, and will also be streamed on the ASH annual meeting platform for virtual participants.
Friday, December 5, 2025, 3:00 p.m. - 6:00 p.m.
Workshop Schedule
Session Description
OPENING REMARKSSpeaker:
Megan Weivoda, PhD
Mayo Clinic
Rochester,
MN, United States
OPENING REMARKS
The Natural Intervention: Diet and Exercise-Based Strategies for Reversing Hematologic Aging
3:03 p.m. - 3:44 p.m., OCCC - W312
Session Description
This session will focus on diet and lifestyle-based strategies to combat hematologic aging.
The speakers will advocate the position that… hematologic aging can be meaningfully reversed through targeted lifestyle interventions. Non-pharmacologic strategies, including modulation of the gut microbiome, structured physical activity, and dietary paradigms, offer synergistic and system-wide rejuvenation of hematopoietic function. Therefore, lifestyle interventions should serve as a first-line approach to reverse hematologic aging.
Speakers:
Nadine Abdallah, MD
Mayo Clinic
Rochester,
MN, United States
Moderator Introduction and Audience Pre-Session Polling
Joshua Bliss, MD, PharmD
New York Presbyterian Hospital
Jersey City,
NJ, United States
The Role of Exercise and Digital Monitoring in Counteracting Aging in Cancer Patients
Mary Riwes, DO
University of Michigan
Ann Arbor,
MI, United States
Prebiotic Interventions to Modulate Gut Microbiota and Inflammation to Prevent Transplant-related Aging
Charity Oyedeji, MD
Duke University School of Medicine
Durham,
NC, United States
Targeting Aging in Sickle Cell Disease Through Exercise and Nutrition
Nadine Abdallah, MD
Mayo Clinic
Rochester,
MN, United States
Panel Discussion and Cross-Examination of the Position; Post-Session Polling
Session Description
This session will focus on immune strategies that are being developed to mitigate aging and the potential for these approaches to combat hematologic aging.
The speakers will advocate the position that… the immune system itself is the master regulator of hematologic aging, and its reprogramming offers unmatched therapeutic leverage. CAR-T therapy, checkpoint blockade, and vaccine strategies can be utilized to strategically engineer the immune system to clear dysfunctional cells and extend the hematologic healthspan
Speakers:
Sheng Li, PhD
University of Southern California
South Pasadena,
CA, United States
Moderator Introduction
Marcos Garcia Teneche, BS
Sanford Burnham Prebys Medical Discovery Institute, Peter Adams Lab
La Jolla,
CA, United States
Restoring T-Cell Homeostasis to Limit Age-dependent Leukemia Progression
Haitham Abdelhakim, MD
University of Kansas Medical Center
Kansas city,
KS, United States
Immune Checkpoint Blockade as a Strategy for Reversing Hematologic Aging
Sheng Li, PhD
University of Southern California
South Pasadena,
CA, United States
Panel Discussion and Cross-Examination of the Position; Post-Session Polling
Small Molecules, Big Impact: Reversing Hematologic Aging by Targeting Senescence and Inflammaging
4:35 p.m. - 5:16 p.m., OCCC - W312
Session Description
This session will focus on small molecules targeting senescence and inflammation for combatting hematologic aging.
The speakers will advocate the position that… small molecule interventions offer distinct advantages in addressing the underlying drivers of aging at a cellular and systemic level. These medications are accessible, scalable, and a potentially safer alternative to immune engineering. By targeting specific pathways that drive senescence and inflammaging, small molecules offer the possibility to rejuvenate the hematopoietic niche, improve immune system function, and restore blood health with minimal invasiveness
Speaker:
Jane Liesveld Jr, MD
University of Rochester
Rochester,
NY, United States
Rapamycin and the Rewiring of Aging
A New Horizon in Hematology: Novel Strategies for Reversing Aging
5:16 p.m. - 5:57 p.m., OCCC - W312
Session Description
This session will focus on novel strategies, such as PROTAC and CRISPR-based technologies, to combat hematologic aging.
The speakers will advocate the position that…the future of hematologic rejuvenation lies in precisely engineered therapies that target the underlying molecular causes of aging. Novel molecular strategies are poised to revolutionize our ability to reverse hematologic aging at a cellular and genetic level. These cutting-edge therapies have the potential to transform the hematologic landscape by not only slowing the aging process but actively reversing it at the cellular and molecular levels.
Speakers:
Conor Lynch, PhD
H. Lee Moffitt Cancer Center And Research Institute
Tampa,
FL, United States
Moderator Introduction
Jonathan Yen, PhD
St. Jude Children's Research Hospital
Memphis,
TN, United States
Precision Editing: Harnessing CRISPR to Rejuvenate Blood Cells
Conor Lynch, PhD
H. Lee Moffitt Cancer Center And Research Institute
Tampa,
FL, United States
Panel Discussion and cross-examination of the position; post-session polling
Friday, December 5, 2025, 3:00 p.m. - 6:00 p.m.
Workshop Schedule
Session Description
Speaker:
Dunia Hatabah
Emory University
Atlanta,
GA, United States
Opening Remarks
Session Description
Challenges of predicting disease severity for early intensification of treatment to prevent future complications and mortality.
Speakers:
Jane Hankins, MD,MS
St Jude Children's Research Hospital
Memphis,
TN, United States
Moderator Introduction: Topic Only
Elizabeth Klings
Boston University
Boston,
MA, United States
Prior Disease Severity Scoring Systems
Courtney Thornburg
Rady Children's Health - Orange County
Orange,
CA, United States
Defining Disease Severity for NHLBI Innovative Trials
Tarun Aurora, MD, MSCI
Emory University
Atlanta,
GA, United States
A New Severity Classification System (SCOGS)
Jane Hankins, MD,MS
St Jude Children's Research Hospital
Memphis,
TN, United States
Engagement/Discussion/Q&A
Session Description
The hunt for surrogate biomarkers for disease severity and end points in SCD: Where are we now?Speakers:
Caterina Minniti, MD
Einsten College of Medicine
Chevy Chase,
MD, United States
Moderator Introduction
Patrick Hines, MD
Functional Fluidics
Detroit,
MI, United States
Adhesions and Red Cell Health as a Marker of Propensity of VOC
Martin Steinberg
Boston Univ. School of Medicine
Boston,
MA, United States
HbF is the Most Powerful Disease Modifier in SCD: What is Next for This Biomarker?
Vence L. Bonham Jr, J.D.
National Human Genome Research Institute
Bethesda,
MD, United States
Patient Reported Outcomes, Indicators of Severity and End Points for Clinical Trials
Caterina Minniti, MD
Einsten College of Medicine
Chevy Chase,
MD, United States
Engagement/Discussion/Q&A
Acute Vaso-occlusive Pain Clinical Trial Endpoints Beyond Time-to-Crisis-Resolution in Sickle Cell Disease (SCD)
4:35 p.m. - 5:15 p.m., OCCC - W315
Session Description
Acute Vaso-occlusive Pain Clinical Trial Endpoints Beyond Time-to-Crisis-Resolution in SCD
Speakers:
Claudia R. Morris, MD
Emory University School of Medicine
Atlanta,
GA, United States
Moderator Introduction
Claudia R. Morris, MD
Emory University School of Medicine
Atlanta,
GA, United States
Challenges with Time-to-Crisis-Resolution as an Endpoint in Acute SCD Pain Clinical Trials
Nitya Bakshi, MBBS, MS
Yale University
New Haven,
CT, United States
Challenges with PROs in Acute SCD Pain Clinical Trials: Why We Need Surrogate Biomarkers
Sruti Shiva
University of Pittsburgh
Pittsburgh,
PA, United States
Mitochondria as a Surrogate Biomarker: Much more than ATP Makers
Claudia R. Morris, MD
Emory University School of Medicine
Atlanta,
GA, United States
Engagement/Discussion/Q&A
Session Description
Considering how to fill known gaps in SCD clinical trial design, a multi-viewpoint discussion.Speakers:
Dunia Hatabah
Emory University
Atlanta,
GA, United States
Moderator Introduction
Dunia Hatabah
Emory University
Atlanta,
GA, United States
Panel Discussion/Q&A
Friday, December 5, 2025, 3:00 p.m. - 5:55 p.m.
Workshop Schedule
Session Description
OPENING REMARKSSpeaker:
Marcin W Wlodarski, MD, PhD
St. Jude Children's Research Hospital
Memphis,
TN, United States
Opening Remarks
Session Description
This overaching session will explore how model organisms and innovative experimental approaches are illuminating the path of pathophysiology of HMs and BMF disorders across multiple genetic backgrounds.Speakers:
Gina Keiffer, MD
Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University
Philadelphia,
PA, United States
Moderator Introduction
Simona Colla, PhD
The University of Texas MD Anderson Cancer Center
Houston,
TX, United States
U2AF1S34 Mutations Activate Telomerase to Overcome Telomere Dysfunctions in Patients with Telomere Biology Disorders
Melvin Thomas III, PhD
St. Jude Children's Research Hospital
Cordova,
TN, United States
Characterizing the in Vivo Impact of Inflammation on Mutant Samd9l Hematopoietic Phenotypes
Stanley Lee, PhD
Fred Hutch
Seattle,
WA, United States
Uncovering the Pathogenic Mechanisms of DDX41 Mutations in Myeloid Malignancies
Ayana Kon, MD, PhD
Univ.Tokyo Kyoto Univesity Dept.Pathology and Tumor Biology
Kyoto,
Japan
Mechanistic Insights into Biallelic and Monoallelic DDX41 Mutations in Myeloid Neoplasms
Sharon Singh, MD
University Of Michigan
Ann Arbor,
MI, United States
The Mechanism of Defective Erythropoiesis in DBA Syndrome
Elif Cenik, PhD
University of Texas
Austin,
TX, United States
Differential Impacts of Ribosomal Protein Haploinsufficiency on Mitochondrial Function
Neha Prasad, PhD
Cleveland Clinic
Cleveland,
OH, United States
Activation of Stress-Activated Protein Kinase in Bone Marrow Failure Ribosomopathies
Ribosomopathies: From Diamond-Blackfan Anemia to Shwachman-Diamond Syndrome and Beyond
3:49 p.m. - 4:36 p.m., OCCC - W307
Session Description
This focused session will address advances in understanding the molecular mechanisms underlying ribosomopathies and their progression to malignancy.Speakers:
Alan Warren, PhD, FRCP, FRCPath
University of Cambridge
Cambridge,
England, United Kingdom
Moderator Introduction
Alexandra Russo Sr, MD
Universitätsmedizin der Johannes Gutenberg- Universität Mainz
Mainz,
Germany
Decoding Epitranscriptomic Drivers of Malignancy: RNA Modopathies Beyond the Genetic Code
Alyssa Cull, PhD
University of York
York,
England, United Kingdom
Emerging Genetic Technologies Inform Personalized Medicine Approaches in Shwachman-Diamond Syndrome
Sarada Ketharnathan, PhD
CHEO Research Institute
Ottawa,
ON, Canada
Leveraging Metabolic Alterations for the Development of Pre-Emptive Leukemia Therapies in Dyskeratosis Congenita and Shwachman-Diamond Syndrome
Felicia Andresen, MD, PhD
Boston Children's Hospital
Boston,
MA, United States
Concordance Of Somatic Genetic Testing in Blood Vs. Bone Marrow in Shwachman-Diamond Syndrome
Jonathan Roelof Adriaan de Wilde
UMC Utrecht
Utrecht,
Netherlands
Activation Of Pyruvate Kinase by Mitapivat Potentially Rescues Ineffective Erythropoiesis in Models of Diamond Blackfan Anemia
Yirun Miao, PhD
St. Anna Children's Cancer Research Institute
Vienna,
Austria
Investigating The Role of a Ribosome Biogenesis Factor in A DBA-Like Congenital Bone Marrow Failure Syndrome
Session Description
This focused session will examine how deleterious germline variants in genes encoding components of DNA repair pathways lead to BMF/HMs and potential therapeutic approaches.Friday, December 5, 2025, 3:05 p.m. - 6:00 p.m.
Workshop Schedule
The Evolving Role Of Exercise, Obesity, Microbiome, And Diet In Cancer Immunotherapy
3:05 p.m. - 4:35 p.m., OCCC - W304ABCD
Session Description
This session will examine how lifestyle and metabolic factors shape immune responses to cancer therapies. Experts will discuss emerging evidence on the microbiome, nutrition, obesity, and physical activity as modulators of efficacy and toxicity, highlighting translational opportunities for patient care.The Evolving Role Of Sex, Inflammation And Aging In Cancer Immunotherapy
4:31 p.m. - 5:57 p.m., OCCC - W304ABCD
Session Description
This session will explore how intrinsic host factors—including sex differences, chronic inflammation, and aging—affect responses to cancer immunotherapy. Presentations will focus on mechanistic insights and strategies to optimize treatment outcomes across diverse patient populations.Friday, December 5, 2025, 3:00 p.m. - 5:50 p.m.
Workshop Schedule
Session Description
OPENING REMARKSSpeaker:
Lisa Baumann Kreuziger, MD, MS
Versiti Medical Sciences Institute
Menomonee Falls,
WI, United States
OPENING REMARKS
Session Description
This session explores how coagulation and fibrinolytic pathways drive cancer biology beyond hemostasis, shaping tumor progression, immune responses, and the tumor microenvironment. By integrating insights from pancreatic cancer and glioblastoma, the presentations highlight emerging mechanisms and therapeutic opportunities at the intersection of coagulation and oncology.Speakers:
Lisa Baumann Kreuziger, MD, MS
Versiti Medical Sciences Institute
Menomonee Falls,
WI, United States
Moderator Introductions
Matthew Flick, PhD
UNC Blood Research Center
Chapel Hill,
NC, United States
uPA/uPAR and tPA to the Pathogenesis of Pancreatic Cancer
Anthony Sloan, PhD
Cleveland Clinic
Cleveland,
OH, United States
Sex Differences in PAR4 Signaling Influencing Glioblastoma Growth
Robert Flaumenhaft, MD
Harvard University
Newton,
MA, United States
Panel Discussion/Q&A
Pathophysiology and Prediction of Thrombosis in Patients with Cancer
4:04 p.m. - 5:45 p.m., OCCC - W304EFGH
Session Description
This session examines the multifaceted biology of cancer-associated thrombosis, spanning immune checkpoint blockade, extracellular vesicles, tumor–vascular interactions, and metabolic drivers of coagulation. Speakers will highlight experimental and clinical insights into how the tumor microenvironment primes thromboinflammation and clot formation. The program also emphasizes advances in risk stratification, with new approaches to predicting venous thromboembolism in glioma and through bone marrow pathology assessment.Speakers:
Marina Marchetti, PhD
Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII
Bergamo,
Italy
Moderator Introductions
Keith McCrae, MD
Cleveland Clinic
Cleveland,
OH, United States
Mechanisms of Immune Checkpoint Inhibitor Causing Thrombosis
Serena Lucotti, PhD
Weill Cornell Medicine
New York City,
NY, United States
Role of Extracellular Vesicles and Lung Macrophages in CAT
Saran Lotfollahzadeh, MD, MMSc
Boston University School of Medicine
Boston,
MA, United States
Tryptophan Upregulation of Coagulation Factors Promotion Cancer Associated Thrombosis
Craig Horbinski, MD, PhD
Northwestern University
Chicago,
IL, United States
Predictors of VTE in Glioma
Alan Aberdeen, MS
Ground Truth Labs
London,
London, United Kingdom
Prediction of Thrombosis From Bone Marrow Pathology
Friday, December 5, 2025, 3:00 p.m. - 6:00 p.m.
Workshop Schedule
Session Description
Opening RemarksSpeakers:
Sarah Skuli, MD, PhD
University of Pennsylvania
Philadelphia,
PA, United States
Opening Remarks
Aaron Schimmer, MD PhD
Princess Margaret Cancer Centre, University of Toronto
Toronto,
ON, Canada
Opening Remarks
Session Description
This session will also highlight fundamental discoveries related to the functional importance of mitochondria and metabolism in normal hematopoiesis with the goal of extending these observations to malignant hematology.Speakers:
Maria Laura Amaya, MD PhD
University of Colorado
Aurora,
CO, United States
Moderator Introduction
Nicola Vannini, PhD
Ludwig Institute for Cancer Research Lausanne
Epalinges,
Switzerland
The Metabolism of Immune Aging
Jose A Cancelas, MD, PhD
Dana-Farber Cancer Institute
Cincinnati,
OH, United States
Mitochondrial Dependencies of Normal Hematopoiesis
Maria Laura Amaya, MD PhD
University of Colorado
Aurora,
CO, United States
Panel Discussion/Q&A
Translational Research - Targeting Mitochondria and Metabolism in Cancer
4:05 p.m. - 5:05 p.m., OCCC - W414AB
Session Description
This session will highlight new mitochondrial and metabolic vulnerabilities in blood cancer and how they vulnerabilities might be targeted with new therapies.Speakers:
Chris Halsey, PhD
University of Glasgow
Glasgow,
Scotland, United Kingdom
Moderator Introduction
Michaela Reagan, PhD
MaineHealth
South Portland,
ME, United States
Obesity and Adipocytes in Multiple Myeloma from Biology to Therapy
Jeevisha Bajaj, PhD
University of Rochester Medical Center
Pittsford,
NY, United States
Metabolic Vulnerabilities of Leukemic Stem Cells
Chris Halsey, PhD
University of Glasgow
Glasgow,
Scotland, United Kingdom
Panel Discussion/Q&A
Session Description
This session will discuss early phase clinical trials of novel agents targeting mitochondrial and metabolic pathways in patients with blood cancer.Speakers:
Marina Konopleva, MD, PhD
Montefiore Einstein Comprehensive Cancer Center
New York,
NY, United States
Moderator Introduction
Takeshi Fujino, MD, PhD
Sloan Kettering Institute
Washington,
MD, United States
Mitochondrial Transplantation For The Treatment of MDS
Ashkan Emadi, MD, PhD
Department of Medical Oncology, WVU School of Medicine WVU Cancer Institute
Morgantown,
WV, United States
Cutting Glutamine, Halting Translation: A Metabolic Therapy in Blood Cancer
Marina Konopleva, MD, PhD
Montefiore Einstein Comprehensive Cancer Center
New York,
NY, United States
Panel Discussion/Q&A
Friday, December 5, 2025, 3:00 p.m. - 6:00 p.m.
Workshop Schedule
Session Description
Opening RemarksSpeaker:
Pamela Sue Becker, MD,PhD
City of Hope
Duarte,
CA, United States
OPENING REMARKS
Session Description
This session aims to introduce the concept of functional precision medicine, and its application to hematological malignancies. Speakers will describe a wide range of approaches for drug sensitivity profiling, e.g., AI-based phenotyping, intra-leukemia heterogeneity, combination screen, apoptotic priming and discuss successes as well as challenges in their clinical application and the integration with genomics.Speakers:
Jun J Yang, PhD
St. Jude Campus
Memphis,
TN, United States
Moderator Introduction
Tea Pemovska, PhD
Medical University of Vienna
Vienna,
Austria
Rethinking How We Treat Disease Through High-Throughput Drug Response Phenotyping
Heikki Kuusanmäki, PhD
University of Helsinki
Helsinki,
Finland
High throughput multiparameter flow cytometry and intra-leukemia heterogeneity in drug response
Patrick Bhola, PhD
Dana-Farber Cancer Institute
Boston,
MA, United States
Apoptosis-Priming as a Measurement of Drug Sensitivity
Krister Wennerberg, PhD
University of Copenhagen
Copenhagen,
Denmark
How to Define Response: The Drug Sensitivity Score
Tea Pemovska, PhD
Medical University of Vienna
Vienna,
Austria
Panel Discussion
Session Description
This session will feature discussion related to computational biology and systems biology approached in drug response prediction and also the dynamic process of clonal evaluation as a means of acquiring drug resistance. Importantly, we will end the workshop with a discussion on the pros and cons of functional precision medicine, e.g., has the science advanced/progressed enough? What is the burden of evidence for clinical utility, what are the regulatory hurdles?Speakers:
Mika Kontro, MD, PhD
Helsinki University Hospital
Helsinki,
Finland
Moderator Introduction
Guangrong Qin, PhD
Institute for Systems Biology
Seattle,
WA, United States
Systems Biology and Machine Learning to Predict Response
Timothy Ley, MD
Washington University in St. Louis
Saint Louis,
MO, United States
Chemoresistance Occurring Before or After AML Therapy: Are They the Same?
Mika Kontro, MD, PhD
Helsinki University Hospital
Helsinki,
Finland
Panel Discussion: Integration of Functional and Genomic Precision Medicine, are we there yet?
Friday, December 5, 2025, 3:00 p.m. - 6:00 p.m.
Workshop Schedule
Session Description
Scientific WorkshopsSpeaker:
Panagiotis Ntziachristos Jr, PhD
Ghent University
Ghent,
Belgium
OPENING REMARKS
Session Description
The impact of epigenetic mechanisms in tumor cells and tumor microenvironment controlling resistance to therapy in myeloid and lymphoid malignancies will be discussed.Speakers:
Panagiotis Ntziachristos Jr, PhD
Ghent University
Ghent,
Belgium
Moderator Introduction
Kimberly Stegmaier Jr, MD
Dana-Farber Cancer Institute
Boston,
MA, United States
Identification of New Vulnerabilities in Therapy Resistance AML
Taishi Yonezawa Jr, PhD
Baylor College of Medicine (BCM)
Houston,
TX, United States
Targeting Post-Translational Regulation of DNMT3A Offers a Promising Therapy for Clonal Hematopoiesis and Hematologic Malignancies
Aristotelis Tsirigos
NYU School of Medicine
New York,
NY, United States
Dissecting the Regulatory Landscape of Leukemias with Multi-Modal AI Models of Gene Regulation
Panagiotis Ntziachristos Jr, PhD
Ghent University
Ghent,
Belgium
Panel Discussion/Q&A
Session Description
RNA splicing, RNA stability, post-transcriptional modifications and associated mechanisms will be discussed in this session. This session will also focus on the role of the interaction of tumor cell with the microenvironment and immune system in disease resistance and the impact of aberrant splicing and epitranscriptomics on these interactions.Speakers:
Lili Wang Jr, MD,PhD
City of Hope
Duarte,
CA, United States
Moderator Introduction
Benson M. George
DFCI
Boston,
MA, United States
Identification and Therapeutic Targeting of Cell Surface RNA-Binding Proteins
Lili Wang Jr, MD,PhD
City of Hope
Duarte,
CA, United States
Splicing Control in Leukemia and Beyond
Lili Wang Jr, MD,PhD
City of Hope
Duarte,
CA, United States
Panel Discussion/Q&A
Session Description
This session will focus on translational efficacy and post-translational modifications and their impact in oncogenesis and resistance to therapy.Speakers:
Daniel Starczynowski, PhD
Cincinnati Children's Hospital
Cincinnati,
OH, United States
Moderator Introduction
Anastasia N. Tikhonova, Assistant Professor
University Health Network
Toronto,
ON, Canada
Immune Microenvironment Defining Responses of Lymphoblastic Leukemia
Theodoros Karantanos Jr, MD, PhD
Johns Hopkins University
Baltimore,
MD, United States
Inflammatory Pathways Foster Treatment Resistance in Myeloid Neoplasms
Quinlan Sievers Jr
Memorial Sloan Kettering
New York,
NY, United States
Molecular and Structural Basis of Pan-Resistance to BTK Targeting Therapies via BTK A428D Mutation
Daniel Starczynowski, PhD
Cincinnati Children's Hospital
Cincinnati,
OH, United States
Panel Discussion/Q&A
Session Description
Speakers:
Shruti Bhatt, PhD
National University of Singapore, Department of Pharmacy and Pharmaceutical Sciences
Singapore,
Singapore
Moderator Introduction
Quinlan Sievers Jr
Memorial Sloan Kettering
New York,
NY, United States
Talk #1: Targeting Macrophage Metabolism to Overcome Chemoresistance in Myeloid Leukemia
Christina Mayerhofer
MGH
Cambridge,
MA, United States
Talk #2: OGFOD1 enables AML chemo- and nutrient stress resistance by regulating protein synthesis
Paolo Gallipoli Jr
Queen Mary University of London
London,
England, United Kingdom
Talk #3: Adipocytic niche protects AML cells from FLT3 inhibitor therapy by activating the PI3 kinase pathway and rescuing their central carbon metabolism
Shruti Bhatt, PhD
National University of Singapore, Department of Pharmacy and Pharmaceutical Sciences
Singapore,
Singapore
Panel Discussion/Q&A
Friday, December 5, 2025, 3:00 p.m. - 6:00 p.m.
Workshop Schedule
Session Description
OPENING REMARKSSpeaker:
Torsten Haferlach I
MLL Munich Leukemia Laboratory
Munchen,
Germany
OPENING REMARKS
Session Description
This session explores advances in circulating tumor DNA (ctDNA) analysis for B-cell lymphomas, highlighting its role in disease monitoring, clonal evolution detection, and measurable residual disease (MRD) assessment. Presentations will cover personalized whole-genome sequencing approaches, real-world applications during CAR T-cell therapy, and international experiences providing a comprehensive view of ctDNA's evolving clinical utility.Speakers:
Wencke Walter
MLL Munich Leukemia Laboratory
München,
Germany
Moderator Introduction
Daniel Hodson Jr, MD, PhD
Cambridge Stem Cell Institute
Cambridge,
ENG, United Kingdom
Talk #3: The UK DIRECT Study; a Roadmap for ctDNA in aggressive B cell lymphoma
Torsten Haferlach I
MLL Munich Leukemia Laboratory
Munchen,
Germany
Panel - Interactive ctDNA MRD case studies in B-cell lymphoma
New Developments in Measurable Residual Disease for Patients with Acute Myeloid Leukemia
4:38 p.m. - 5:57 p.m., OCCC - W311ABCD
Session Description
This session focuses on emerging strategies and technologies for measurable residual disease (MRD) detection and management in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Presentations will cover guideline updates, advances in molecular and single-cell approaches, and the clinical integration of MRD-guided therapies to inform treatment decisions and improve outcomesSpeakers:
Ella Thompson, PhD
Peter MacCallum Cancer Centre
Melbourne,
Victoria, Australia
Moderator Introduction
Laura Dillon Jr
Virginia Tech FBRI Cancer Research Center
Washington,
DC, United States
Talk #2: Measurable residual FLT3 internal tandem duplication in acute myeloid leukemia
Linde A Miles Jr, PhD
Cincinnati Children's Hospital Medical Center
Cincinnati,
OH, United States
Talk #3: Single cell proteogenomics for AML MRD?
R. Coleman Lindsley Jr, MD, PhD
Dana-Farber Cancer Institute
Boston,
MA, United States
Talk #4: Integrating serial molecular quantification in MDS/AML
Sun Loo, MBBS
Peter MacCallum Cancer Centre and Royal Melbourne Hospital
Melbourne,
Victoria, Australia
Talk #5: Clinical application of MRD-directed therapy
Ella Thompson, PhD
Peter MacCallum Cancer Centre
Melbourne,
Victoria, Australia
Panel - Interactive case studies in AML MRD
67th ASH Annual Meeting and exposition
Registration for ASH members, non-members, groups, exhibitors, and media is now open!